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Abstract
Background: Complete and partial trisomy 9 is the fourth most common chromosomal disorder. It is also
associated with various congenital characteristics affecting the cranio-facial, skeletal, central nervous,
gastrointestinal, cardiac and renal systems. Very few cases have been reported in adults. Partial trisomy 9q is also
associated with short stature, poor growth and growth hormone deficiency. This is the first reported case of an
extensive endocrinology investigation of short stature in trisomy 9q and the outcome of growth hormone
treatment.
Case Presentation: The case involves a 23-year-old female of pure partial trisomy 9q. The case involves a 23-year
old female with pure partial trisomy 9q involving a duplication of 9q22.1 to q32, de novo, confirmed by genetic
studies using fluorescene in situ hybridization (FISH) method. The diagnosis was at 6 years of age. She did not
demonstrate all the congenital morphologies identified with trisomy 9q disorders especially in relation to multi-
organ morphologies. There is also a degree of associated intellectual impairment. At prepuberty, she was referred
for poor growth and was diagnosed with partial growth hormone deficiency. She responded very well to
treatment with growth hormone and is currently living an independent life with some support.
Conclusions: Trisomy 9q is associated with short stature and failure to thrive. Growth hormone deficiency should
be identified in cases of trisomy 9q and treatment offered. This is the first reported case of response to growth
hormone replacement in partial trisomy 9.
Background
Complete and partial trisomy 9 is the fourth most com-
mon chromosomal disorder with over 150 reported
cases in the literature [1]. It is associated with cranio-
facial abnormalities, failure to thrive, pyloric stenosis,
gastro-oesophageal reflux and various defects in cardio-
vascular, central nervous, gastrointestinal and renal sys-
tems. Growth hormone deficiency has been described
with complete and partial trisomy 9. The complete form
of trisomy 9 is associated with early death while very
few cases of partial trisomy 9 has been reported in
young adults. We present a case of partial trisomy 9q in
an adult patient which is, to the best of our knowledge,
the first reported case in two aspects: a novel mutation
and her response to growth hormone treatment.
Case Presentation
The female patient was delivered following an unevent-
ful pregnancy via caesarean section for placenta praevia
at 35 weeks gestation with a birth weight of 2.18 kg.
The mother, aged 29 years, gave no history of exposure
to radiation or mutagens. The immediate family mem-
bers were healthy and had had normal development.
She exhibited dysmorphic features: broad forehead, cir-
cular ears, widely spaced nipples, hypertelorism and
deep set eyes. The child was noted to be developing
slowly from 6 months, in particular fine and gross
motor skills. She walked at the age of 30 months. Psy-
chological assessments led to her receiving education
support for learning difficulties, labile emotions and
anxiety whilst attending main stream schooling. At 4
years she was growing poorly (Ht SDS -4.0, Wt SDS
-4.0).
The child was fully investigated at 6 years. Genetic
testing revealed additional genetic material of indetermi-
nate source at chromosome 9q 22. The parents had nor-
mal chromosomal pattern. Pituitary function studies
(including insulin tolerance test) revealed partial GH
deficiency (peak GH level 15.7U / l )w h i l s tg o n a d o t r o -
phin, cortisol, and thyroid studies were normal. Renal
ultrasound was normal.
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height of 115 cm (SDS -3.0) and weight of 23kgs (SDS
-2.0). Biochemical and clinical investigations were
repeated (Table 1 and 2). Glucose tolerance was normal.
Sleep and exercise GH studies supported the diagnosis
of GH deficiency (though these studies were performed
without sex steroid priming). Bone age was 11.0 years
(Greulich and Pyle) with a delay of 3 years. GnRH sti-
mulation test suggested a pre-pubertal response (LH
peak, 3.4 U/l [normal pubertal peak >5.0]; FSH peak, 9.9
U/l [1.0-8.0]) as did pelvic ultrasound showing prepu-
bertal uterus and ovaries. GH therapy was commenced
at 15.6 years on the basis of extreme short stature, slow
growth and partial GH deficiency. GH therapy was
administered for 3 years, initially 3 mg/wk and increased
to 8.6 mg/wk. There was an excellent response to GH
therapy; IGF-I normalized and a further growth of 23
cm (Figure 1)(Table 1). At the age of 16 years, she
entered puberty and achieved menarche at 18 years,
with subsequent regular menstrual cycle.
At 23 years of age, the patient was re-evaluated. She
had intellectual impairment and some obsessive compul-
sive behaviour. Further dysmorphic features were appar-
ent: broad forehead, short neck, low set ears (Figure 2)
and wide gap between the first and second toes. She
had nasal speech, perhaps secondary to velo-pharyngeal
insufficiency. Echocardiogram and renal ultrasound were
normal. A MRI of brain was normal including the pitui-
tary gland except for an abnormal appearance of the
corpus callosum with thickening of genu and rostrum.
Endocrine investigations were normal apart from low
IGF-I level (Table 1). Repeat chromosome analysis with
detailed band analysis with Vysis probe and fluorescene
in sit hybridization (FISH) with subtelomere probe and
ABL specific probe on 9q34 (Abbott-Vysis, Downer’s
Grove, Il) revealed a pure partial trisomy of chromo-
some 9 from band 9q22.1 to 9q32 with the additional
genetic material considered a duplication of the long
arm of chromosome 9 (Figure 3 &4).
Conclusions
Complete trisomy 9 is associated with spontaneous
abortion and those surviving pregnancy rarely live
beyond childhood. Subjects with partial trisomy 9 seem
to have better prognosis with few reported cases of
reaching adulthood [2]. The aetiology and risk factors
for this condition are not known [2]. Suspicion of com-
plete and partial trisomy 9 can be identified and con-
firmed by chorionic venous sampling in the first
trimester or later by amniocentesis [3].
The chromosome studies in our patient indicated
breakpoints very similar to a previous report of an infant
with trisomy 9q and multiple congenital abnormalities
together with GH deficiency [4]. Our case did not
demonstrate all of the previously reported abnormalities
seen in other cases of trisomy 9q [4-6]. As with our
case, impaired psychomotor development is common in
trisomy 9q, although normal psychomotor development
has been described (Table 3) [7]. The MRI demon-
strated features of corpus callosum dysgenesis and it has
been suggested that all individuals with different kinds
Table 1 Biochemical analysis of a female with partial trisomy 9q treated with growth hormone
Age (years) 15 18 23 Ref range
Morning Growth hormone (mU/l) < 0.5 < 0.5
Post exercise peak growth hormone (mU/l) 0.7 >10
Sleep test growth hormone (mU/l) 0.8 >10
Insulin like growth factor I (nmol/l) 8.0 57 16 20-80
Insulin growth factor BP3 (mg/l) 1.0 140 1.6-4.0
Follicle stimulating hormone (U/l) 2.0 4.0 2.0 1.0-8.0
Luteinizing hormone (U/l) < 0.5 11 38 1.0-12.0
Oestradiol (pmol/l) 37 287 369 Prepubertal: <100
Postpubertal: >200
Prolactin (mU/l) 255 71-556
Thyroid stimulating hormone (mU/l) 1.79 2.2 0.30-5.00
Free thyroxine (pmol/l) 14.1 11.0 10.0-25.0
Morning cortisol (nmol/l) 288 389 200-700
Fasting glucose (mmol/l) 4.5 4.0-6.0
Oral glucose tolerance test 2 h value (mmol/l) 7.6 <8.9
Table 2 Clinical staging at 15 and 18 years of age
Tanner staging Age 15 yrs Age 18 yrs
Breast development (stage) 1 3
Pubic hair growth (stage) 1 3
Bone age (years) 11 14 (mature)
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because of the high risk of structural disorder affecting
the central nervous system with this disorder [1].
As a patient with partial trisomy 9, she survives into
adulthood and as a consequence she has multiple physi-
cal and psychological challenges. The degree of deformi-
ties in trisomy 9 is associated with the degree of
trisomic cell expression in various organs. Our patient
had relatively minimal dysmorphic features which could
be consistent with the degree of duplication of external
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Figure 1 Height with growth hormone treatment.G r o w t h
Hormone treatment started at 15 years 8 months and stopped at
19 years 2 months.
Figure 2 Adult female with trisomy 9q illustrating the facial
features and the hands.
Figure 3 FISH analysis with whole chromosome 9 paint and ABL gene specific probes (band 9q34.1).
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the benefits of GH therapy. Trisomy 9q has been shown
to have GH deficiency (Table 3) but have not been trea-
ted with GH, and although our patient only had partial
GH deficiency, she responded very well. The genes for
GH and chorionic somatomammotropin have been
mapped to chromosome 17 [8] and not chromosome 9.
However, the LHX 3 gene, responsible for a rare syn-
drome with combined pituitary hormone deficiency and
pathological pituitary anatomy, is located at 9q34 [9].
Our patient did not demonstrate any other pituitary
deficiency or pituitary defects on MRI, hence, the exact
cause of the GH deficiency is unclear. Growth retarda-
tion is common in chromosome disorders, and is often
attribute to the aneuploidy [10]. One example of such
chromosome disorder with some similarities to partial
trisomy 9q is partial trisomy 1q [10]. Since growth retar-
dation is common in chromosome disorders, we suggest
all patients with partial trisomy 9 to be evaluated for
GH deficiency and GH treatment initiated generously.
Consent
Written consent was obtained from subject and her
mother for the publication of this case report and
accompanying images. A copy of written consent is
available for review.
Table 3 Clinical findings of reported cases of pure partial trisomy 9q with duplication (q22.1!) [4,11-13]
References 1 2 3 4 5
Age 23 years 1 year 17 years 40 years 7 months
Reduced birth weight + +
Failure to thrive + + + +
Learning disability + + + +
Microcephaly + +
Hypertelorism + +
Other facial morphologies + +
High arched palate +
Short neck +
Cardiac abnomalies +
CNS abnomalies + +
Pyloric stenosis + +
Digital abnomalies + + +
Growth hormone deficiency + +
*Hypothyroidism +
*Oesophageal atresia +
Comparison of trisomic sections of partial trisomy 9q
(1) Present study. (2009) 46, XY, dup(9)(q22.1®32) de novo
(2) Heller, A et al. (2000) 46, XX, dup(9)(pter®q22.1::q31.1®q22.1::q31.1
q22.1::q31.1®qter)
(3) Hengstschläger, M et al. (2004) 46, XX, dup(9)(q22.1®q33) de novo
(4) Maraschio et al. (1998) 46, XY, dup(9)(q22.1®q31.3)
Figure 4 Idiogram and partial karyotype revealing duplication
of 9q.
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